New NCCN patient guide for Waldenström's Macroglobulinemia helps make informed treatment decisions
A very rare sub-type of Non-Hodgkin's Lymphoma, Waldenström's Macroglobulinemia affects approximately 1,500 - 2,000 people in the Un...
NCCN publishes new easy-to-understand patient education resources focused on brain cancer
The National Comprehensive Cancer Network has published the NCCN Guidelines for Patients and NCCN Quick Guide sheets for Brain Cancer - Glio...
Global experts meet at IASLC 17th World Conference on Lung Cancer in Vienna
Global lung cancer researchers and patient advocates today emphasized that new models of delivering care and communicating about cancer care...
D.C. Council passes ‘Death with Dignity Act’ by a veto-proof 11-2 margin
Compassion & Choices reports the District of Columbia is poised to become the seventh jurisdiction in the U.S. where medical aid in dyin...
Scientists identify genetic mutations in highly aggressive rhabdoid meningiomas
Meningiomas are the most common primary brain tumors, but the term encompasses over a dozen subtypes that range from benign to highly aggres...
Fred Hutchinson opens first-of-its-kind clinic to provide new immunotherapies for cancer patients
Fred Hutchinson Cancer Research Center today announced the official opening of a first-of-its-kind clinic dedicated to providing innovative ...
Scientists discover new option for treating malignant pleural mesothelioma
Researchers at the Comprehensive Cancer Center of MedUni Vienna and Vienna General Hospital have discovered a new option for treating malign...
NCCN publishes new resources to help patients understand treatment options for stomach cancer
This year, it is estimated that more than 26,000 people will be diagnosed with Stomach Cancer in the United States, with nearly one million ...
New NCCN Imaging AUC released for eight new cancers
The National Comprehensive Cancer Network, a Centers for Medicare & Medicaid Services-approved provider-led entity for imaging appropria...
Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein
Cancer remains a leading cause of death worldwide, and the global cancer burden is expected to increase by 70 percent over the next two deca...
Novel combination therapy slows cancer growth in patients with advanced solid tumors
A phase 1 clinical trial testing a novel combination therapy developed by scientists at VCU Massey Cancer Center slowed the growth of cancer...
NCCN educational resources provide insight for patients with Mycosis Fungoides
Mycosis Fungoides is a very rare form of lymphoma affecting approximately 1,000 people per year in the United States. from News-Medical.Ne...
PD surgery improves quality of life in patients with malignant pleural mesothelioma
Although surgery can prolong the lives of patients with an aggressive type of cancer called malignant pleural mesothelioma, many patients av...
AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016
AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive oncology pipeline at...
NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma
It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016. The sixt...
International scientists discuss new treatments for non small cell lung cancer
More than 30 prominent international scientists gathered to discuss the state-of-the-art, as well as promising future approaches for the tre...
New drug shows promise against mesothelioma
A new drug is showing promise as a treatment for mesothelioma - one of the most lethal cancers of all. from News-Medical.Net Mesothelioma ...
ONCOblot test shows promise in early detection of malignant mesothelioma
MorNuCo Laboratories of West Lafayette, Indiana, and their ONCOblot Test recently completed a retrospective clinical trial focusing on the e...
Bevacizumab extends survival of pleural mesothelioma patients
Patients with unresectable, malignant pleural mesothelioma derive a significant survival benefit from the addition of bevacizumab to standar...
Four unrelated families share identical BAP1 mutation that causes several cancers
University of Hawai'i Cancer Center researchers discovered members of four families, apparently unrelated and living in different states...